Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post-hoc analysis from the randomized controlled PRE-D trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Metabolic effects of 1-week binge drinking and fast food intake during Roskilde Festival in young healthy male adults

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Distinct signaling by insulin and IGF-1 receptors and their extra- and intracellular domains

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Differential effects of bile acids on the postprandial secretion of gut hormones: a randomized crossover study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Evidence for glucagon secretion and function within the human gut

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

AIM: To assess the effects of dapagliflozin, metformin and exercise treatment on changes in plasma glucagon concentrations in individuals with overweight and HbA1c-defined prediabetes.

MATERIALS AND METHODS: One-hundred and twenty individuals with overweight (body mass index ≥ 25 kg/m 2 ) and prediabetes (HbA1c of 39-47 mmol/mol) were randomized to a 13-week intervention with dapagliflozin (10 mg once daily), metformin (850 mg twice daily), exercise (30 minutes of interval training 5 days per week) or control (habitual living). A 75-g oral glucose tolerance test (OGTT) (0, 30, 60 and 120 minutes) was administered at baseline, at 13 weeks (end of intervention) and at 26 weeks (end of follow-up). Linear mixed effects models with participant-specific random intercepts were used to investigate associations of the interventions with fasting plasma glucagon concentration, insulin/glucagon ratio and glucagon suppression during the OGTT.

RESULTS: At baseline, the median (Q1; Q3) age was 62 (54; 68) years, median fasting plasma glucagon concentration was 11 (7; 15) pmol/L, mean (SD) HbA1c was 40.9 (2.3) mmol/mol and 56% were women. Compared with the control group, fasting glucagon did not change in any of the groups from baseline to the end of the intervention (dapagliflozin group: -5% [95% CI: -29; 26]; exercise group: -8% [95% CI: -31; 24]; metformin group: -2% [95% CI: -27; 30]). Likewise, there were no differences in insulin/glucagon ratio and glucagon suppression during the OGTT between the groups.

CONCLUSIONS: In individuals with prediabetes, 13 weeks of treatment with dapagliflozin, metformin or exercise was not associated with changes in fasting or post-OGTT glucagon concentrations.

Original languageEnglish
JournalDiabetes, Obesity and Metabolism
Volume23
Issue number2
Pages (from-to)530-539
Number of pages10
ISSN1462-8902
DOIs
Publication statusPublished - Feb 2021

    Research areas

  • exercise, glucagon, metformin, obesity, prediabetes, sodium-glucose co-transporter-2 inhibitor

ID: 61210447